R&D channel feed

Chan Zucker­berg Ini­tia­tive funds four grants to cre­ate re­gion­al net­works of re­searchers

Last year

Iron­wood’s stock drops 40% as short bow­el syn­drome drug shows mixed ef­fi­ca­cy in PhI­II

Last year

No­vo Nordisk plans for life af­ter We­govy, set­ting up roots in Boston to try and find its fu­ture

Last year
Pharma

Palatin’s stock plum­mets 43% as lead as­set fails PhI­II dry eye co-pri­ma­ry end­points

Last year

Vi­a­tris li­cens­es Idor­sia’s PhI­II heart and lu­pus drugs with $350M up­front

Last year
Deals

Bris­tol My­ers eyes In­dia as home of its largest site out­side US by 2025, maps $400M Ire­land ex­pan­sion

Last year
Pharma
Manufacturing

Viking’s GLP-1/GIP re­cep­tor ag­o­nist helped pa­tients lose al­most 15% of their body weight over 13 weeks

Last year

Janux shares up 90% as T cell en­gager shows ear­ly signs of PSA re­sponse in prostate can­cer

Last year

UK biotech draws Pfiz­er back­ing in £40.5M Se­ries A for pep­tide-in­spired drugs

Last year
Financing

Celldex’s CSU drug could chal­lenge a No­var­tis can­di­date af­ter PhII

Last year

J&J to close Cal­i­for­nia R&D fa­cil­i­ty with plans to open new 'in­no­va­tion cen­ter'

Last year
Pharma

Boehringer In­gel­heim un­veils mid-stage win for glucagon/GLP-1 can­di­date for MASH, kin­dling PhI­II plans

Last year

GSK’s an­tibi­ot­ic suc­ceeds in late-stage gon­or­rhea tri­al with eye to ad­dress­ing re­sis­tance

Last year

Eu­ro­pean reg­u­la­tor rec­om­mends ap­proval of Carvyk­ti in ear­li­er lines of mul­ti­ple myelo­ma

Last year
FDA+

Am­gen wants in on obe­si­ty. But it's still work­ing on rare dis­ease, too

Last year
Pharma

Clade Ther­a­peu­tics cuts staff and ap­pears to shut down Eu­ro­pean sub­sidiary

Last year
People

Due to in­creas­ing com­pe­ti­tion, Gala­pa­gos’ CAR-T ex­its au­toim­mune dis­eases

Last year

FDA grants pri­or­i­ty re­view for Dupix­ent in COPD, sets June ap­proval de­ci­sion dead­line

Last year
FDA+

Clin­i­cal tri­al starts slowed to be­low pre-pan­dem­ic lev­els last year, IQVIA analy­sis finds

Last year
Cell/Gene Tx

Mod­er­na wants an ac­cel­er­at­ed ap­proval for its can­cer vac­cine — but it's wait­ing on three things

Last year
Pharma

Al­ny­lam CEO de­fends changes to cru­cial AT­TR tri­al: 'We re­al­ly are play­ing to win'

Last year

Amy­lyx’s ALS drug tastes bit­ter. What would make it bet­ter? More patent life

Last year
Pharma

Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Last year
Pharma
Coronavirus

Re­searchers de­tail da­ta from first 15 au­toim­mune dis­ease pa­tients treat­ed with CAR-T — and out­stand­ing ques­tions

Last year
Cell/Gene Tx
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times